Share: Facebook Twitter LinkedIn
Activity Provided By:


Warm Autoimmune Hemolytic Anemia (wAIHA)

Access Activity

Overview / Abstract:

Warm autoimmune hemolytic anemia (wAIHA) is the most common type (60-70%) of autoimmune hemolytic anemia (AIHA). In most cases, wAIHA is due an immunoglobulin G (IgG) autoantibody that binds to red blood cells (RBC), leading to hemolysis.

Current recommendations for managing people with wAIHA are largely based on case series and retrospective studies involving off-label medications. Also, while there are currently no medications specifically approved to treat wAIHA, data are emerging on new therapies under investigation which may impact treatment in the future.

This 60-minute CME program, hosted by Irina Murakhovskaya, MD, of the Montefiore Medical Center, Albert Einstein College of Medicine, in New York, NY and Bruno Fattizzo, MD, of the University of Milan and Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, in Milan, Italy, describes current best practices for diagnosing and managing patients with wAIHA.


May 31, 2024


Physician CME, Physician Assistant CME


Webinar / Webcast / Video

Credits / Hours

1.0 hour


American Academy of CME

Presenters / Authors / Faculty

Irina Murakhovskaya, MD
Montefiore Medical Center
Albert Einstein College of Medicine
New York, NY

Bruno Fattizzo, MD
University of Milan
Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico
Milan, Italy

Sponsors / Supporters / Grant Providers

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Keywords / Search Terms

CheckRare rare disease, rare blood disorder, Warm autoimmune hemolytic anemia, wAIHA, autoimmune hemolytic anemia, AIHA, immunoglobulin G, IgG autoantibody, red blood cells, hemolysis Free CE CME

Access Activity

CORE Higher Education Group,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps.CORE Higher Education Group,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the Terms of Service. Site Map